



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/075,355	02/14/2002	Hildegard M. Kramer	5190	8887
75	90 06/15/2004		EXAM	INER
GENZYME CORPORATION			WOITACH, JOSEPH T	
15 PLEASANT STREET CONNECTOR P.O. BOX 9322		ART UNIT	PAPER NUMBER	
FRAMINGHAM, MA 01701-9322			1632	

DATE MAILED: 06/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

1
\$-
9

*	Application No.	Applicant(s)			
	10/075,355	KRAMER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Joseph T. Woitach	1632			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	i6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONE	ely filed  will be considered timely. he mailing date of this communication. 0 (35 U.S.C. § 133).			
Status					
<ul> <li>1) ⊠ Responsive to communication(s) filed on 14 February 2002.</li> <li>2a) ☐ This action is FINAL. 2b) ⊠ This action is non-final.</li> <li>3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is</li> </ul>					
closed in accordance with the practice under E.	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims					
4) ☐ Claim(s) 1-54 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-54 are subject to restriction and/or e					
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the d Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner	pted or b) objected to by the E lrawing(s) be held in abeyance. See on is required if the drawing(s) is obje	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)    Notice of References Cited (PTO-892)   Notice of Draftsperson's Patent Drawing Review (PTO-948)   Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Paper No(s)/Mail Date	4) Interview Summary ( Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	e			

Application/Control Number: 10/075,355 Page 2

Art Unit: 1632

**DETAILED ACTION** 

This application claims benefit to provisional application 60/268,559, filed February 14,

2001.

Claims 1-53 are pending.

Election/Restrictions

Applicant's election with traverse of Group 1, claims 1-13, 15, 16, in the reply filed on

April 16, 2004, is acknowledged. The traversal is on the ground(s) that the Examiner has failed

to provide a rationale for restricting the methods from the products made. Examiner notes that

Applicants are correct and has set forth a new restriction is set forth below. Examiner wishes to

apologize for any inconvenience this may have caused Applicants.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-13, 15, 16, drawn to a method of making a biocompatible fleece

comprising providing solution of a macromer that is hydrophilic, biodegradable

and a cross-linking moiety; freezing the solution into the desired shape and cross-

linking into a fleece/matrix, classified in class 530, subclass 333.

II. Claims 14, 17-20, 22, 24-36, 48, 49 and 57, drawn to a biocompatible fleece,

classified in class 530, subclass 402.

Application/Control Number: 10/075,355

Art Unit: 1632

III. Claims 21, 23 and 50, drawn to a biocompatible fleece comprising cells, classified in class 435, subclass 325.

IV. Claims 37-37, 52 and 53, drawn to a method of treatment of a wound or defect by applying a slurry of fleece particles, classified in class 530, subclass 333.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case while the products are claimed as a product by process the product can be made by other methods known in the art. Further, the process can be used to generate different products as evidenced by the claims of groups II and III.

Inventions II and III are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP § 806.04(b), 3rd paragraph), and the species are patentably distinct (MPEP § 806.04(h)). In the instant case, the intermediate product is deemed to be useful by itself as a slurry (as set forth in claim 37) or as a substrate for a variety of other uses and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this

Application/Control Number: 10/075,355

Art Unit: 1632

is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Inventions II, III and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the general methods of treatment can be accomplished with different matrices or the same matrices made by different means. Further, the product can be used in non-treatment methods, such as providing a substrate to culture cells. With respect to group II only claim 47 recites the delivery of a cell, and this can be accomplished as set forth above, with other matrices.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, have acquired a separate status in the art because of their recognized divergent subject matter, and the search required for each group is not co-extensive with the remaining groups, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (571) 272-0734.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

Cal Doilete